SGCB and chronic obstructive pulmonary disease: Accordingly, on the basis that alterations to the sGC-cGMP-PKG axis may underlie skeletal muscle atrophy in COPD, we hypothesized that pharmacological activation of the guanylyl cyclase pathway may provide a beneficial therapeutic strategy in the treatment of muscle dysfunction in COPD.